University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (31)

2024

  1. Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis

    Scientific Reports, Vol. 14, Núm. 1

  2. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

    Clinical Cancer Research, Vol. 30, Núm. 7, pp. 1319-1326

  3. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  4. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

  5. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

    Cell Reports Medicine, Vol. 5, Núm. 6

2022

  1. A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data

    Bioinformatics, Vol. 38, Núm. 21, pp. 4885-4892

  2. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  3. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

    The Lancet Haematology, Vol. 9, Núm. 10, pp. e756-e765

  4. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia

    Leukemia, Vol. 36, Núm. 8, pp. 2097-2107

  5. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia

    Leukemia and Lymphoma, Vol. 63, Núm. 13, pp. 3154-3164

  6. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

  7. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

    Experimental Hematology, Vol. 115, pp. 44-53

2021

  1. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

    Blood Cancer Journal

  2. Hematopoiesis under telomere attrition at the single-cell resolution

    Nature Communications, Vol. 12, Núm. 1

  3. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia

    Leukemia Research, Vol. 101

2020

  1. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

    Leukemia and Lymphoma, Vol. 61, Núm. 6, pp. 1493-1499

  2. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes

    Leukemia, Vol. 34, Núm. 3, pp. 872-881

2019

  1. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

    Blood Advances, Vol. 3, Núm. 6, pp. 922-933

2018

  1. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

    Oncotarget, Vol. 9, Núm. 11, pp. 9714-9727

  2. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

    Blood Advances, Vol. 2, Núm. 19, pp. 2491-2504